Single and Repeat Doses of DMT in Healthy Subjects

Phase 1 Active not recruiting 60 enrolled Algernon Pharmaceuticals Centre for Human Drug Research, Netherlands · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This study aims to assess the safety and tolerability of single ascending, and fixed repeated doses of N,N-Dimethyltryptamine (DMT) in healthy subjects, when given by intravenous (IV) infusion.

Timeline

Start: 2023-01-13
Primary completion: 2026-03
Completion: 2026-03

Publications

van der Heijden KV, Zuiker RGJA, Otto ME, Bryan CS, Stewart N, Stillwell C, De Kam ML, van Leuken MB, van Gerven JMA, Jacobs GE. Safety, Pharmacokinetics, and Pharmacodynamics of a 6-h N,N-Dimethyltryptamine (DMT) Infusion in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Trial. Clin Transl Sci. 2025 May;18(5):e70234. doi: 10.1111/cts.70234.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	N,N-Dimethyltryptamine	Unknown	0.105 mg	Intravenous
Subject	N,N-Dimethyltryptamine	Unknown	0.525 mg	Intravenous
Subject	N,N-Dimethyltryptamine	Unknown	0.7875 mg	Intravenous

Single and Repeat Doses of DMT in Healthy Subjects

Summary

Timeline

Publications

Drugs

Indications